Coherus Oncology announced it will report its first quarter 2026 financial results after market close on May 11, 2026. The company will hold a conference call and webcast at 5:00 p.m. Eastern Time to discuss the results and provide a business update. Coherus is a commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and ongoing clinical trials for other cancer treatments. Investors can access the webcast and replay via the company’s investor website.
Bitdeer sold 223.1 BTC this week and reported zero Bitcoin holdings on its corporate balance sheet, maintaining a strategy of fully liquidating its mined Bitcoin rather than holding it. This approach prioritizes liquidity to support operations and gr...
Revolut will stop supporting the stablecoin USDT on August 31, 2026, due to the European Union's new Markets in Crypto-Assets (MiCA) regulations. Users can buy USDT until July 6 and deposit until July 30, with the option to sell or transfer USDT unti...
Candel Therapeutics is shifting from a risky clinical-stage biotech to a late-stage oncology company, driven by its lead asset CAN-2409 which showed positive Phase III results in localized prostate cancer. Additional promising data in non-small cell ...
The paper company reported Q1 EBITDA slightly above expectations despite weather disruptions, supported by lower industry supply, declining imports, price increases, and better utilization rates. Conservative recovery assumptions estimate an adjusted...
MediaAlpha reported Q1 revenue of $310 million and adjusted EBITDA of $31.4 million, surpassing guidance due to increased participation from insurance carriers and strong growth in property and casualty (P&C) insurance. The company now generates 93% ...
